Four companies in the Asia Pacific region have taken out licenses with The Medicines Patent Pool (MPP) to manufacture generic versions of Tasigna (nilotinib). 22 June 2023
Seagen has announced latest efficacy and safety results from Part C of a Phase II trial of Adcetris (brentuximab vedotin) alongside nivolumab and standard chemo 13 June 2023
Legend Biotech Corporation and Janssen have announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administrati 8 June 2023
A post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and 5 June 2023
Industry analyst GlobalData has outlined the driving factors in hematology, identifying Ultomiris (ravulizumab), Hemlibra (emicizumab) and Vafseo (vadadustat) a 22 May 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.